Senior Director, Clinical Development
IDEAYA Biosciences
Summary
IDEAYA is seeking a Senior Director, Clinical Development to join the Development team. The Senior Director, Clinical Development will serve as the physician leader for IDE849 and possibly additional assets, with full accountability for clinical strategy, study execution, and scientific integrity through registration. This individual will own the medical voice for their clinical programs, both internally and externally.
Job description
Position Summary
IDEAYA is seeking a Senior Director, Clinical Development to join the Development team. The Senior Director, Clinical Development will serve as the physician leader for IDE849 and possibly additional assets, with full accountability for clinical strategy, study execution, and scientific integrity through registration. This individual will own the medical voice for their clinical programs, both internally and externally.
In the near term, the primary focus will be IDE849, encompassing a registrational study in post-tarlatamab ES-SCLC, a registrational study in 2L+ NEC, and an active combination program with durvalumab and IDE161 (PARG inhibitor) targeting first-line SCLC. Additional priorities include initiating a frontline strategy for IDE849 and providing leadership for other areas of clinical development.
What you'll do
Clinical Strategy & Study Design
- Assume immediate ownership of the Clinical Development Plan (CDP) and Target Product Profile (TPP) for IDE849 across SCLC and NEC indications
- Lead protocol design and amendments for the IDE849-001 master study, including the Phase 3 SCLC RCT registrational arm, the NEC registrational study, and the IDE849 + IDE161 combination program
- Refine dose optimization strategy, randomized dose expansion design, and endpoint selection in alignment with FDA guidance
- Drive the accelerated approval strategy for both SCLC (post-tarlatamab) and NEC (DLL3-unselected), including ORR/DOR endpoint design and OS confirmatory endpoint planning for SCLC
Medical Monitoring & Safety
- Serve as medical monitor for IDE849-001; review safety data on an ongoing basis across all cohorts
- Lead Safety Review Committee meetings and interface with the external Data Safety Monitoring Board (DSMB)
- Oversee toxicity monitoring
- Author and review medical sections of protocols, INDs, investigator brochures, clinical study reports, and BLA submissions
Regulatory & Health Authority Engagement
- Lead preparation for and participation in FDA meetings including SCLC dose optimization discussions
- Drive Breakthrough Therapy Designation strategy and submission (targeted Q1 2027)
- Support Fast Track and Orphan Drug Designation applications as appropriate
- Partner with Regulatory Affairs on global development strategy, including EU and other ex-US health authority interactions
External Engagement
- Build and maintain relationships with key opinion leaders in thoracic oncology, neuroendocrine tumors, and other relevant tumor types
- Represent IDEAYA at major scientific conferences, including ASCO and ESMO
- Support investigator identification and engagement across the approximately 200 planned IDE849-001 sites and other asset study sites
- Contribute to publication strategy; author and co-author manuscripts and abstracts
Cross-Functional Leadership
- Serve as the medical lead on the IDE849 Program Team, providing direction across Clinical Operations, Translational Medicine, Regulatory Affairs, CMC, and Commercial functions
- Partner with Translational Medicine on DLL3 CDx strategy, including the Ventana/Roche IHC development program, prospective and retrospective biomarker analysis
- Collaborate with Business Development on potential DLL3 T-cell engager partnership strategy for first-line SCLC
- Provide medical input on competitive intelligence and commercial positioning for the DLL3 ADC franchise
Requirements
- MD or MD/PhD required
- Board certification or eligibility in Medical Oncology, Hematology/Oncology, or Pulmonary Oncology strongly preferred
- Minimum 12 years of oncology clinical development experience in the pharmaceutical or biotechnology industry
- Direct experience designing and executing Phase 1, 2, and 3 oncology trials, including dose escalation and expansion studies
- Solid understanding of FDA accelerated approval pathways, ORR/DOR endpoint strategy, and confirmatory study requirements
- Experience in thoracic oncology — SCLC, NSCLC, NEC, or related tumor types — in either clinical practice or industry drug development
- Strong GCP knowledge and familiarity with IND and BLA regulatory requirements
- Experience with ADC programs — ideally with TOP1i payload agents — and familiarity with ADC-class toxicities, including ILD
- Prior experience in neuroendocrine tumors (epNEC, LCNEC, GEP-NEC) in either a clinical or drug development setting
- Familiarity with DLL3 biology and the competitive SCLC treatment landscape, including tarlatamab, ZL-1310, and B7-H3 ADC programs
- Experience with novel-novel combination development and contribution-of-components regulatory strategy
- Prior FDA Type B, C and/or D meeting experience; BTD submission experience a plus
- Established KOL relationships across multiple oncology indications
- Publication record in SCLC, NEC, or ADC oncology
Benefits
- Medical, Dental & Vision
- 401(k)
- ESPP
- Wellness Programs
- Short-Term Incentive Plan
- Stock Option Awards
Company overview
IDEAYA Biosciences is a clinical-stage precision medicine oncology company headquartered in South San Francisco, California. Founded in 2015, the company is dedicated to the discovery, development, and commercialization of transformative therapies for cancer patients. IDEAYA's innovative approach integrates expertise in small-molecule drug discovery, structural biology, and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers. The company focuses on developing tailored, potentially first-in-class targeted therapies aligned with the genetic drivers of disease, with a primary emphasis on synthetic lethality – an emerging class of precision medicine targets. IDEAYA has built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. The company's mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized, with the goal of altering the course of disease and improving clinical outcomes for cancer patients. IDEAYA went public on NASDAQ in May 2019 (NASDAQ: IDYA) and has established strategic collaborations with major pharmaceutical companies including Pfizer, Gilead Sciences, and GlaxoSmithKline.